Legal & General Group PLC Mei Pharma, Inc. Transaction History

Legal & General Group PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 22, 2022	SELL	$0.42 - $0.65 $5,784 - $8,952	-13,773 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$0.54 - $2.74 $1,580 - $8,019	2,927 Added 26.99%	13,773 $8,000
Q2 2021 Aug 12, 2021	SELL	$2.6 - $3.65 $7,927 - $11,128	-3,049 Reduced 21.94%	10,846 $31,000
Q1 2021 May 17, 2021	BUY	$2.73 - $4.5 $4,935 - $8,136	1,808 Added 14.96%	13,895 $48,000
Q3 2020 Nov 13, 2020	SELL	$2.46 - $4.27 $11,143 - $19,343	-4,530 Reduced 27.26%	12,087 $38,000
Q2 2020 Aug 14, 2020	BUY	$1.45 - $4.3 $1,228 - $3,642	847 Added 5.37%	16,617 $69,000
Q1 2020 May 14, 2020	BUY	$0.75 - $2.55 $1,217 - $4,138	1,623 Added 11.47%	15,770 $23,000
Q4 2019 Feb 13, 2020	BUY	$1.65 - $2.48 $4,458 - $6,700	2,702 Added 23.61%	14,147 $35,000
Q2 2019 Aug 14, 2019	BUY	$2.45 - $3.32 $28,040 - $37,997	11,445 New	11,445 $29,000

Ticker MEIP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 133,261,000
Market Cap $366M
Description
MEI Pharma, Inc., a late-stage pharmaceutical company, focuses on the development and commercialization of various therapies for the treatment of cancer. The company develops Zandelisib, an oral phosphatidylinositol 3-kinase delta inhibitor that is in Phase III clinical trial for the treatment of patients with relapsed/refractory follicular lymp...

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

Stay updated on Legal & General Group PLC with notifications on news.